Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: A NICE single technology appraisal

PharmacoEconomics

Volumn 31, Issue 8, 2013, Pages 653-661

  Tosh, Jonathan ^a   Archer, Rachel ^a   Davis, Sarah ^a   Stevenson, Matt ^a   Stevens, John W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; INFECTION; INJECTION SITE REACTION; MONOTHERAPY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SHORT FORM 36; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878833833     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0052-7     Document Type: Review

References (41)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE; 2009.
2. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347-9.
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351-62.
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439-48.
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133-40.
6. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
7. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051-62.
8. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35-46.
9. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137-46.
10. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257-70.
11. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483-95.
12. Burch J, Griffin S, McKenna C, et al. Omalizumab for severe persistent asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991-1004.
13. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119-32.
14. Kilonzo M, Hislop J, Elders A, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(1):15-24.
15. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(2):101-10.
16. Spackman E, Rice S, Norman G, et al. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(3):185-94.
17. Rafia R, Simpson E, Stevenson M, et al. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal. Pharmacoeconomics (In press).
18. Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. 2013;. doi: 10.1007/s40273-013-0036-7.
19. Greenhalgh J, Bagust A, Boland A, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. Pharmacoeconomics (In press).
20. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics (In press).
21. Kearns B, Lloyd Jones M, Stevenson M, et al. Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics (In press).
22. Faria R, Spackman E, Burch J, et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. PharmacoEconomics (In press).
23. Symmons D. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002;41(7):793-800.
24. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000;39(1):28-33.
25. Hyrich KL, Watson KD, Lunt M, et al. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford). 2011;50(1):117-23.
26. National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: NICE; 2009.
27. Deighton C, O'Mahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009;338:b702.
28. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130). London: NICE; 2007.
29. National Institute for Health and Clinical Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186). London: NICE; 2010.
30. National Institute for Health and Clinical Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195). London: NICE; 2010.
31. National Institute for Health and Clinical Excellence. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234). London: NICE; 2011.
32. National Institute for Health and Clinical Excellence. Tocilizumab for the treatment of rheumatoid arthritis (TA247). London: NICE; 2012.
33. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
34. Jackson R, Tosh J, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs: a single technology appraisal. Sheffield: ScHARR; 2010.
35. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68(6):789-96.
36. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964-75.
37. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210-21.
38. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81.
39. Hurst NP, Kind, P, Ruta D, Hunter M, Stubbings, A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology. 1997;36:551.
40. National Institute for Health and Clinical Excellence. Rheumatoid arthritis (after failure of previous antirheumatic drugs): golimumab - appraisal consultation document. London: NICE; 2010. http://guidance.nice.org.uk/TA/ Wave19/53/Consultation/DraftGuidance. Accessed 26 Mar 2013.
41. National Institute for Health and Clinical Excellence. Final appraisal determination: golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs. London: NICE; 2011.